Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators believe dexmedetomidine will provide superior sedation with reduced side effects and reduced time to discharge compared with pentobarbital. The investigators have developed sedation protocols with pentobarbital and dexmedetomidine in our ambulatory procedure center. These protocols are both routinely used for sedation in our unit. The investigators propose to study these two protocols in children ages 6 months to 6 years presenting to the ambulatory procedure center for non-painful procedural sedation. The investigators will compare failure of sedation, side effect profile, recovery and discharge times between the two pharmacologic protocols.
| Condition | Intervention |
|---|---|
|
Sedation |
Drug: dexmedetomidine sedation protocol Drug: pentobarbital sedation protocol |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Subject) |
| Official Title: | Dexmedetomidine Versus Pentobarbital Sedation Protocol for Non-painful Procedural Sedation in Pediatrics |
- failure of sedation [ Time Frame: day of sedation ] [ Designated as safety issue: No ]
- side effect profile [ Time Frame: 48 hours ] [ Designated as safety issue: No ]
- post-sedation recovery and discharge time [ Time Frame: day of sedation ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 120 |
| Estimated Study Completion Date: | June 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Dexmedetomidine sedation protocol
|
Drug: dexmedetomidine sedation protocol
Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
Other Name: Precedex
|
|
Active Comparator: 2
Pentobarbital sedation protocol
|
Drug: pentobarbital sedation protocol
Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation. May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation. Other Name: Nembutal
|
Eligibility| Ages Eligible for Study: | 6 Months to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Requiring sedation for non-painful procedures
- Normal airway per exam
Exclusion Criteria:
- Congenital syndromes with known difficult airways
- Known difficult airway during past anesthesia or sedation experience
- Parent/guardian refusal of participation
Contacts and Locations
More Information
Publications:
| Responsible Party: | Lynne Sterni, MD, Washington University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00878345 History of Changes |
| Other Study ID Numbers: | colegroenersterni |
| Study First Received: | April 7, 2009 |
| Last Updated: | November 6, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Washington University School of Medicine:
|
Pediatric sedation Pentobarbital Dexmedetomidine Procedural sedation in children |
Additional relevant MeSH terms:
|
Pentobarbital Dexmedetomidine Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs GABA Modulators GABA Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents |
ClinicalTrials.gov processed this record on June 17, 2013